Freestone Grove Partners’s DexCom DXCM Stock Holding History

Freestone Grove Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,254	Closed	-$219K	–	783
2025 Q3	$219K	Buy	+3,254	New	+$258K	﹤0.01%	655
2025 Q1	–	Sell	-100,015	Closed	-$7.78M	–	642
2024 Q4	$7.78M	Buy	+100,015	New	+$7.4M	0.1%	212

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Freestone Grove Partners's DXCM Position: Q4 2025 in Review

Freestone Grove Partners sold out of DexCom (DXCM) in Q4 2025, closing a stake of 3,254 shares — an estimated $219K sold.

Freestone Grove Partners first reported a position in DXCM in Q4 2024 and held it in 2 quarters. The position peaked at $7.78M in Q4 2024. 922 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Freestone Grove Partners reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
Freestone Grove Partners sold 3,254 DexCom shares in Q4 2025, an estimated $219K.
Freestone Grove Partners first reported a position in DexCom in Q4 2024 and held it in 2 quarters.
Freestone Grove Partners's DexCom position peaked at $7.78M in Q4 2024.
922 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.